TY - JOUR
T1 - Advancing diagnostics to address antibacterial resistance
T2 - The diagnostics and devices committee of the Antibacterial Resistance Leadership Group
AU - Tsalik, Ephraim L.
AU - Petzold, Elizabeth
AU - Kreiswirth, Barry N.
AU - Bonomo, Robert A.
AU - Banerjee, Ritu
AU - Lautenbach, Ebbing
AU - Evans, Scott R.
AU - Hanson, Kimberly E.
AU - Klausner, Jeffrey D.
AU - Patel, Robin
AU - Caliendo, Angie
AU - Chiu, Charles
AU - Humphries, Romney
AU - Miller, Melissa
AU - Woods, Chris
N1 - Funding Information:
Financial support. The development of this article was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH; UM1AI104681). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© The Author 2017.
PY - 2017
Y1 - 2017
N2 - Diagnostics are a cornerstone of the practice of infectious diseases. However, various limitations frequently lead to unmet clinical needs. In most other domains, diagnostics focus on narrowly defined questions, provide readily interpretable answers, and use true gold standards for development. In contrast, infectious diseases diagnostics must contend with scores of potential pathogens, dozens of clinical syndromes, emerging pathogens, rapid evolution of existing pathogens and their associated resistance mechanisms, and the absence of gold standards in many situations. In spite of these challenges, the importance and value of diagnostics cannot be underestimated. Therefore, the Antibacterial Resistance Leadership Group has identified diagnostics as 1 of 4 major areas of emphasis. Herein, we provide an overview of that development, highlighting several examples where innovation in study design, content, and execution is advancing the field of infectious diseases diagnostics.
AB - Diagnostics are a cornerstone of the practice of infectious diseases. However, various limitations frequently lead to unmet clinical needs. In most other domains, diagnostics focus on narrowly defined questions, provide readily interpretable answers, and use true gold standards for development. In contrast, infectious diseases diagnostics must contend with scores of potential pathogens, dozens of clinical syndromes, emerging pathogens, rapid evolution of existing pathogens and their associated resistance mechanisms, and the absence of gold standards in many situations. In spite of these challenges, the importance and value of diagnostics cannot be underestimated. Therefore, the Antibacterial Resistance Leadership Group has identified diagnostics as 1 of 4 major areas of emphasis. Herein, we provide an overview of that development, highlighting several examples where innovation in study design, content, and execution is advancing the field of infectious diseases diagnostics.
KW - Antibacterial Resistance
KW - Devices
KW - Diagnostics
UR - http://www.scopus.com/inward/record.url?scp=85023188558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023188558&partnerID=8YFLogxK
U2 - 10.1093/cid/ciw831
DO - 10.1093/cid/ciw831
M3 - Article
C2 - 28350903
AN - SCOPUS:85023188558
SN - 1058-4838
VL - 64
SP - S41-S47
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -